WO2000040273A8 - Treatment of viral diseases using an interferon omega expressing polynucleotide - Google Patents

Treatment of viral diseases using an interferon omega expressing polynucleotide

Info

Publication number
WO2000040273A8
WO2000040273A8 PCT/US1999/030843 US9930843W WO0040273A8 WO 2000040273 A8 WO2000040273 A8 WO 2000040273A8 US 9930843 W US9930843 W US 9930843W WO 0040273 A8 WO0040273 A8 WO 0040273A8
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral diseases
interferon omega
expressing polynucleotide
polynucleotide
Prior art date
Application number
PCT/US1999/030843
Other languages
French (fr)
Other versions
WO2000040273A3 (en
WO2000040273A2 (en
Inventor
Suezanne Parker
Holly Horton
Original Assignee
Vical Inc
Suezanne Parker
Holly Horton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc, Suezanne Parker, Holly Horton filed Critical Vical Inc
Publication of WO2000040273A2 publication Critical patent/WO2000040273A2/en
Publication of WO2000040273A3 publication Critical patent/WO2000040273A3/en
Publication of WO2000040273A8 publication Critical patent/WO2000040273A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides a method of treating a viral disease comprising administering to a mammal a polynucleotide construct comprising a polynucleotide encoding IFNφ. The polynucleotide construct of the present invention can be administered free from associated with transfection facilitating agents or as a complex with at least one or more cationic lipids.
PCT/US1999/030843 1999-01-08 1999-12-28 Treatment of viral diseases using an interferon omega expressing polynucleotide WO2000040273A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11540399P 1999-01-08 1999-01-08
US60/115,403 1999-01-08

Publications (3)

Publication Number Publication Date
WO2000040273A2 WO2000040273A2 (en) 2000-07-13
WO2000040273A3 WO2000040273A3 (en) 2000-11-16
WO2000040273A8 true WO2000040273A8 (en) 2001-01-11

Family

ID=22361168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030843 WO2000040273A2 (en) 1999-01-08 1999-12-28 Treatment of viral diseases using an interferon omega expressing polynucleotide

Country Status (1)

Country Link
WO (1) WO2000040273A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
IL155730A0 (en) 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
CN100438870C (en) * 2001-11-09 2008-12-03 精达制药公司 Method for treating diseases with omega interferon
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN102274557B (en) 2006-08-09 2014-12-03 精达制药公司 Osmotic delivery systems and piston assemblies
DK2157967T3 (en) 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and applications thereof
LT2462246T (en) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2013095755A (en) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd Cationic lipid
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
EP4221739A1 (en) * 2020-10-02 2023-08-09 Imunon, Inc. Polynucleotide vaccines and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (en) * 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetic sequences, type i interferon peptide coded by them, and these organisms producing the same
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
WO2000040273A3 (en) 2000-11-16
WO2000040273A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
WO2000040273A8 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
WO2001081405A3 (en) Methods and compositions for the prevention and treatment of anemia
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
IL153442A0 (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
WO2002084298A3 (en) Medicaments which are modulators of hm74 and/or hm74a activity
EP1758998A4 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
WO1999003508A3 (en) METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
WO1999002143A3 (en) Medicament comprising adenosine
WO2000009098A3 (en) Method for treating ocular neovascular diseases
WO2001026639A3 (en) Pharmaceutical composition of ateglinide and another antidiabeticagent
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
IL142581A (en) Medicament for treating heart disease
NZ513087A (en) Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease
WO1999021538A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
WO2001014415A3 (en) Egfh2 genes and gene products
AU5155700A (en) Gene therapy of pulmonary disease
WO2001094570A3 (en) Transfection method
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WR Later publication of a revised version of an international search report
122 Ep: pct application non-entry in european phase